e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Novel drugs and biomarkers in respiratory medicine
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Surfactant-enforced treatment of
pseudomonas
-induced pneumonia
A. Birkun (Simferopol, Ukraine)
Source:
Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine
Session:
Novel drugs and biomarkers in respiratory medicine
Session type:
Thematic Poster Session
Number:
734
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Birkun (Simferopol, Ukraine). Surfactant-enforced treatment of
pseudomonas
-induced pneumonia. Eur Respir J 2013; 42: Suppl. 57, 734
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Related content which might interest you:
Development of an antibody therapy for the treatment of pneumonia
Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections
Year: 2016
Modern etiology of severe community-acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues
Year: 2016
Dynamic of adherence to guidelines for antibiotic therapy of community-aquired pneumonia (CAP)
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013
Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Year: 2016
Predictors of treatment failure in patients with bacteremic pneumococcal community-acquired pneumonia
Source: Annual Congress 2013 –Pneumonia and sepsis
Year: 2013
Modification of empirical antibiotic therapy in community acquired pneumonia
Source: International Congress 2014 – Different interesting issues in respiratory infections: 2
Year: 2014
Factors affecting treatment success in community acquired pneumonia (CAP)
Source: Annual Congress 2013 –Pneumonia and sepsis
Year: 2013
Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Clinical impact of a prediction score for drug-resistance in community-onset pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Common organisms causing community acquired pneumonia
Source: Annual Congress 2013 –Bacterial, fungal and mycobacterial infections
Year: 2013
Drug-resistant pathogens prediction scores in CAP, HCAP and immunocompromised
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Clinical characteristics of 11 cases of pulmonary abscess in children
Source: Annual Congress 2013 –Interesting cases of respiratory infections
Year: 2013
30 day mortality and eosinopenia in patients with pneumonia
Source: International Congress 2014 – Different interesting issues in respiratory infections: 1
Year: 2014
Multiple tension pneumatocele due to necrotising pneumonia
Source: Annual Congress 2013 –Interesting cases of respiratory infections
Year: 2013
Can the broad-spectrum antibiotics improve the prognoses of high-risk nursing- and healthcare-associated pneumonia?
Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections
Year: 2014
Should empyema be managed differently in case of necrotizing pneumonia?
Source: Annual Congress 2013 –Pulmonary infection in children: diagnosis and long-term effects
Year: 2013
Shortening duration of antibiotic therapy according to clinical stability in patients with community-acquired pneumonia (CAP)
Source: International Congress 2014 – Respiratory infections: inflammation and treatment
Year: 2014
COPD and pneumonia
Source: International Congress 2015 – Different data in COPD
Year: 2015
Bacteraemia in outpatient with community-acquired pneumonia
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015
Colistin therapy for nosocomial pneumonia and nephrotoxicity
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept